Pharmacogenetics Study of Warfarin by Genotyping of CYP2C9 and VKORC1 Polymorphism to Determination of Sensitivity and Resistance to Warfarin in the Population of Southern Iran

Document Type : Original Article(s)

Authors

1 MD, Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

2 Assistant Professor, Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

3 PhD, Department of Medical Genetic, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran Corresponding Author: Babak Shirazi Yeganeh, Assistant Professor, Department of Pathology, School

Abstract

Background: Since 1950, warfarin has been widely used as an anticoagulant medication for the prevention and treatment of thromboembolism. Various factors such as age, weight, diet, and genetic factors such as CYP2C9 and VKORC1 genes are involved in determining the dose of warfarin. This study was conducted to evaluate common polymorphisms in patients treated with warfarin.
Methods: The present cross-sectional study was conducted in the laboratory of Shahid Dastghib Hospital in Shiraz, Iran, in 2019. A total of 99 patients were selected for this study. Patients were receiving warfarin for various reasons, including heart problems. CYP2C9 and VKORC1 gene polymorphisms were investigated by a multiplex PCR method.
Findings: The haplotype frequencies of CYP2C9 alleles with *1*1, *1*3, *2*3, and *3*3 combinations were 1, 9.1, 19.2, and 70.2 percent, respectively. Among VKORC1 -1639G> A gene, allele GA, by 52.5%, was most frequent, followed by GG and AA with 34.3%, and 13.1% respectively.
Conclusion: The results showed a significant effect of CYP2C9 and VKORC1 gene polymorphisms on the required starting dose of warfarin to maintain INR in the range of 2-3. The CYPC2CP * 3*3* and VKORC1 -1639 G>A alleles were the most common polymorphisms in the studied population. The combination of age, weight, and haplotype genotypes of CYP2C9 and VKORC1 was the best predictive value. We can calculate the weekly dose of warfarin with the regression equation and help determine the starting dose of this drug for people with similar conditions.

Highlights

Babak Shirazi Yeganeh: Google Scholar, PubMed 

Ardeshir Bahmanimeh: Google Scholar, PubMed 

Keywords

Main Subjects

References

  1. Patel S, Preuss CV, Bhutani J, Patel N. Warfarin. Treasure Island (FL): StatPearls Publishing; 2024.
  2. Gedge J. A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. Age Ageing 2000; 29(1): 31-4.
  3. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006; 16(2): 101-10.
  4. Taşkın BD, Kula S, Ergün MA, Altun D, Olguntürk
    R, Tunaoğlu FS, et al. The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population. Anatol J Cardiol 2016; 16(10): 791-6.
  5. Shalia KK, Doshi SM, Parikh S, Pawar PP, Divekar SS, Varma SP, et al. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response. J Assoc Physicians India 2012; 60: 34-8.
  6. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115(18): 3827-34.
  7. Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M, et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 2010; 87(5): 572-8.
  8. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013; 369(24): 2294-303.
  9. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106(1): 135-40.
  10. Tellor KB, Nguyen SN, Bultas AC, Armbruster AL, Greenwald NA, Yancey AM. Evaluation of the impact of body mass index on warfarin requirements in hospitalized patients. Ther Adv Cardiovasc Dis 2018; 12(8): 207-16.
  11. Khoury G, Sheikh-Taha M. Effect of age and sex on warfarin dosing. Clin Pharmacol 2014; 6: 103-6.
  12. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis. JAMA 1999; 282(21): 2058-67.
  13. Wadelius M, Sörlin K, Wallerman O, Karlsson J, Yue QY, Magnusson PKE, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and
    other factors. Pharmacogenomics J 2004; 4(1): 40-8.
  14. Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 2004; 103(7): 2630-5.
  15. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427(6974): 537-41.
  16. Rad F, Hamidpour M, Saadat H, Poopak B. Evaluation of common polymorphism of CYP2C9 in Warfarin-treated patients [in Persian]. Sci J Iran Blood Transfus Organ 2016; 12(4): 340-6.
  17. Tabatabaei SM, Monfaredan A, Bargahi N, Dabiri Oskuei S. Study of polymorphism frequency of 1639G> A gene from VKORC1 in patients with cardiovascular disorders in the northwestern area of Iran [in Persian]. J Arak Uni Med Sci 2012; 15(4): 40-6.
  18. Emadian Razavi F, Zarban A, Hajipoor F, Naseri M. The allele frequency of CYP2C9 and VKORC1 in the Southern Khorasan population. Res Pharma Sci 2017; 12(3): 211-21.
Journal of Isfahan Medical School
Volume 41, Issue 742
2nd Week, January
January and February 2024
Pages 980-987

Files

History

  • Receive Date: 06 January 2023
  • Revise Date: 27 January 2024
  • Accept Date: 27 January 2024

Share

How to cite

Statistics